Literature DB >> 22147264

Advances in the laboratory evaluation of peripheral neuropathies.

Mengjing Chloe Huan1, Mark Bromberg.   

Abstract

Peripheral neuropathy is a common clinical problem in neurology and laboratory testing is an integral part of diagnosis. In the past few years, practice parameters have been published to establish an evidence-based guide to neuropathy testing. There are many tests that are common and accepted in practice, but there is no clear mandate on which tests are necessary. This article reviews recent practice parameter publications as well as other updates in laboratory testing for peripheral neuropathy, including the roles of lipid profile, genetic testing, antibody titers, and B(12) testing in a specific dopamine-treated Parkinson's patients. These can serve as recommendations to help guide laboratory testing.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22147264     DOI: 10.1007/s11910-011-0239-2

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  31 in total

Review 1.  Laboratory evaluation of peripheral neuropathy.

Authors:  Mengjing Chloe Huan
Journal:  Semin Neurol       Date:  2010-10-12       Impact factor: 3.420

Review 2.  Four novel cases of periaxin-related neuropathy and review of the literature.

Authors:  C Marchesi; M Milani; M Morbin; M Cesani; G Lauria; V Scaioli; G Piccolo; G M Fabrizi; T Cavallaro; F Taroni; D Pareyson
Journal:  Neurology       Date:  2010-11-16       Impact factor: 9.910

Review 3.  Autosomal-recessive forms of demyelinating Charcot-Marie-Tooth disease.

Authors:  O Dubourg; H Azzedine; C Verny; G Durosier; N Birouk; R Gouider; M Salih; A Bouhouche; A Thiam; D Grid; M Mayer; M Ruberg; M Tazir; A Brice; E LeGuern
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

4.  Plasma-cell dyscrasia and peripheral neuropathy with a monoclonal antibody to peripheral-nerve myelin.

Authors:  N Latov; W H Sherman; R Nemni; G Galassi; J S Shyong; A S Penn; L Chess; M R Olarte; L P Rowland; E F Osserman
Journal:  N Engl J Med       Date:  1980-09-11       Impact factor: 91.245

5.  Anti-SOX1 antibodies in patients with paraneoplastic and non-paraneoplastic neuropathy.

Authors:  M Tschernatsch; P Singh; O Gross; T Gerriets; N Kneifel; C Probst; S Malas; M Kaps; F Blaes
Journal:  J Neuroimmunol       Date:  2010-08-11       Impact factor: 3.478

6.  Prognosis of polyneuropathy due to IgM monoclonal gammopathy: a prospective cohort study.

Authors:  J M F Niermeijer; K Fischer; M Eurelings; H Franssen; J H J Wokke; N C Notermans
Journal:  Neurology       Date:  2010-02-02       Impact factor: 9.910

7.  A case of severe neuropathy associated with hypertriglyceridemia.

Authors:  Runhua Hou; Anne Carol Goldberg; Garry Stuart Tobin
Journal:  Endocr Pract       Date:  2008-11       Impact factor: 3.443

8.  How useful are anti-neural IgM antibodies in the diagnosis of chronic immune-mediated neuropathies?

Authors:  Eduardo Nobile-Orazio; Francesca Gallia; Fabrizia Terenghi; Silvia Allaria; Claudia Giannotta; Marinella Carpo
Journal:  J Neurol Sci       Date:  2007-10-02       Impact factor: 3.181

9.  Chronic ataxic neuropathies associated with anti-GD1b IgM antibodies: response to IVIg therapy.

Authors:  S Attarian; J Boucraut; A M Hubert; D Uzenot; E Delmont; A Verschueren; J Franques; J P Azulay; J Pouget
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-09-01       Impact factor: 10.154

10.  Elevated triglycerides correlate with progression of diabetic neuropathy.

Authors:  Timothy D Wiggin; Kelli A Sullivan; Rodica Pop-Busui; Antonino Amato; Anders A F Sima; Eva L Feldman
Journal:  Diabetes       Date:  2009-05-01       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.